All In MedTech

Device Trial Radar · NCT07902375

Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

730

Planned (sponsor's estimate)

Start

Jun 19, 2026

Primary completion

Dec 31, 2032

Study completion Dec 31, 2032

Sponsor

Lead sponsor
Universiteit AntwerpenAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University Hospital, Antwerp
First posted
Oct 28, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated device
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of the MYSSELF (Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers) study is to investigate which biological markers (i.e., (epi)genetic biomarkers) found in self-collected samples, such as first-void urine and vaginal samples, are linked to the presence of endometrial, ovarian, vulvar, or vaginal (pre-)cancer or to postmenopausal bleeding. Samples collected by clinicians from the cervix or vulva, as well as blood and tissue samples, will be used for comparison. The study will explore whether these markers could help improve earlier and less invasive detection of gynecological cancers in the future.

Conditions

  • Gynaecological Cancers
  • Ovarian Cancer
  • Endometrial Cancer
  • Vulvar Cancer
  • Vaginal Cancer
  • Postmenopausal Bleeding
  • Early Detection of Cancer

Interventions

  • Colli-Pee 20 mL device with UCMDevice

    Participants will collect a first-void urine (the initial part of the urine stream) sample with the 20 mL Colli-Pee device prefilled with urine conservation medium (UCM, DNA Genotek, Canada). This sample can be taken at home the day before or the day of the planned consultation at the hospital or at the hospital itself.

  • Evalyn BrushDevice

    Participants will collect a vaginal self-sample with the Evalyn Brush (Rovers Medical Devices, The Netherlands) at home the day before or the day of the planned consultation at the hospital or at the hospital itself.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number and overview of biomarkers associated with the presence of gynecological (pre-)cancersTime frame: 48 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Hospital of Antwerp (UZA)

    Edegem, Antwerp, Belgium · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.